Cardiol Therapeutics Analyst Ratings
Cardiol Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Cardiol Therapeutics Analyst Ratings
Cardiol Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Cardiol Therapeutics (CRDL) and MicroPort Scientific (OtherMCRPF)
Cardiol Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Paragon 28 (FNA) and Intra-Cellular Therapies (ITCI)
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Biogen (BIIB) and Nurix Therapeutics (NRIX)
Canaccord Genuity Remains a Buy on Cardiol Therapeutics (CRDL)
Cantor Fitzgerald Reiterates Overweight on Cardiol Therapeutics, Maintains $3 Price Target
Cardiol Therapeutics Analyst Ratings
Canaccord Genuity Adjusts Price Target on Cardiol Therapeutics to $6 From $5, Maintains Buy Rating
Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $6
Cantor Fitzgerald Lowers Price Target to Cardiol Therapeutics to $5 From $6, Maintains Overweight Rating